India, July 27 -- Humacyte, Inc. (HUMA), a biotechnology company developing bioengineered human tissues, announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the first-in-human clinical study of its Coronary Tissue Engineered Vessel (CTEV) in patients undergoing coronary artery bypass grafting (CABG).
CABG is a surgical procedure used to restore blood flow to the heart by bypassing blocked or narrowed coronary arteries in patients with coronary artery disease, one of the leading causes of heart attack and death worldwide.
The current CABG procedure uses autologous blood vessels, primarily the left internal mammary artery or the saphenous vein, to bypass blocke...